BRPI0411831A - métodos de inibição da permeabilidade vascular e apoptose - Google Patents
métodos de inibição da permeabilidade vascular e apoptoseInfo
- Publication number
- BRPI0411831A BRPI0411831A BRPI0411831-6A BRPI0411831A BRPI0411831A BR PI0411831 A BRPI0411831 A BR PI0411831A BR PI0411831 A BRPI0411831 A BR PI0411831A BR PI0411831 A BRPI0411831 A BR PI0411831A
- Authority
- BR
- Brazil
- Prior art keywords
- sphingosine
- methods
- vascular endothelial
- vascular permeability
- apoptosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"MéTODOS DE INIBIçãO DA PERMEABILIDADE VASCULAR E APOPTOSE". Prevêem o agonista dos receptores de esfingosina-1-fosfato endotelial vascular; compostos como FTY720 podem ser fosforilados por cinase-2 esfingosina para as formas fosforiladas que servem como agonistas do receptor de esfingosina-1-fosfato; os agonistas dos receptores de esfingosina-1-fosfato endotelial vascular são empregados em métodos de tratamento de distúrbios de permeabilidade vascular e apoptose de célula endotelial vascular indesejada em um mamífero e para o crescimento de novos vasos sanguíneos; os agonistas dos receptores de esfingosina-1-fosfato endotelial vascular podem ser usados para a fabricação de um medicamento para tratamento de distúrbios de permeabilidade vascular e apoptose de célula endotelial vascular indesejada e para o crescimento de novos vasos sanguíneos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48223403P | 2003-06-24 | 2003-06-24 | |
PCT/US2004/019420 WO2005002559A2 (en) | 2003-06-24 | 2004-06-18 | Methods of inhibiting vascular permeability and apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411831A true BRPI0411831A (pt) | 2006-08-08 |
Family
ID=33563841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411831-6A BRPI0411831A (pt) | 2003-06-24 | 2004-06-18 | métodos de inibição da permeabilidade vascular e apoptose |
Country Status (14)
Country | Link |
---|---|
US (3) | US7838562B2 (pt) |
EP (1) | EP1643983B1 (pt) |
JP (2) | JP2007523858A (pt) |
CN (2) | CN100431534C (pt) |
AT (1) | ATE466572T1 (pt) |
AU (1) | AU2004253473B2 (pt) |
BR (1) | BRPI0411831A (pt) |
CA (3) | CA2778126A1 (pt) |
DE (1) | DE602004027045D1 (pt) |
ES (1) | ES2342396T3 (pt) |
MX (1) | MXPA05014216A (pt) |
PL (1) | PL1643983T3 (pt) |
PT (1) | PT1643983E (pt) |
WO (1) | WO2005002559A2 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003094965A2 (en) | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
JP2008528450A (ja) * | 2005-01-21 | 2008-07-31 | メドベット サイエンス ピーティーワイ. リミティッド | 細胞損傷の治療法 |
KR100773765B1 (ko) | 2005-11-24 | 2007-11-12 | 재단법인서울대학교산학협력재단 | 개선된 스핑고신 유사체의 제조 방법 |
ES2748432T3 (es) * | 2006-09-26 | 2020-03-16 | Novartis Ag | Composiciones farmacéuticas que comprenden un modulador de S1P |
EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
WO2008066750A1 (en) | 2006-11-22 | 2008-06-05 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
HUE027696T2 (en) | 2007-10-12 | 2016-10-28 | Novartis Ag | Preparations containing sphingosine-1-phosphate (S1P) receptor modulators |
CN102464590B (zh) * | 2010-11-18 | 2013-10-23 | 中国科学院上海药物研究所 | 一类免疫调节剂及其制备方法和用途 |
ES2388273B1 (es) * | 2011-03-16 | 2013-10-01 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada |
JP6023308B2 (ja) | 2012-03-26 | 2016-11-09 | アロヨ バイオサイエンセズ リミテッド ライアビリティー カンパニー | 新規なスフィンゴシン1‐リン酸受容体アンタゴニスト |
US9220706B2 (en) * | 2012-06-01 | 2015-12-29 | National Institutes Of Health (Nih) | Inhibition of leukemic stem cells by PP2A activating agents |
US20150258168A1 (en) * | 2012-09-12 | 2015-09-17 | Oklahoma Medical Research Foundation | Modulation of podoplanin mediated platelet activation |
WO2014175287A1 (ja) * | 2013-04-26 | 2014-10-30 | 国立大学法人 京都大学 | 脳動脈瘤の形成および/または増大の抑制若しくは縮小用医薬組成物 |
WO2016035769A1 (ja) * | 2014-09-01 | 2016-03-10 | パスロジ株式会社 | ユーザ認証方法及びこれを実現するためのシステム |
WO2016115092A1 (en) * | 2015-01-12 | 2016-07-21 | La Jolla Institute For Allergy And Immunology | Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
CN105395530A (zh) * | 2015-11-27 | 2016-03-16 | 天津医科大学总医院 | 芬戈莫德的新用途 |
CN105640928A (zh) * | 2016-02-26 | 2016-06-08 | 南京医科大学 | Fty720在制备预防与治疗缺血性脑卒药物中的应用 |
CN115120724A (zh) * | 2017-05-22 | 2022-09-30 | 北京蔚蓝之源医药科技有限公司 | 治疗再生障碍性贫血的方法和药物组合物 |
US20210113529A1 (en) | 2018-02-02 | 2021-04-22 | Kyoto University | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
EP3677259A1 (en) * | 2019-01-07 | 2020-07-08 | Mosaiques Diagnostics And Therapeutics AG | Use of arachidonyl trifluoromethyl ketone |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2167805A1 (en) * | 1993-07-23 | 1995-02-02 | L. David Tomei | Methods of treating apoptosis and associated conditions |
US5948820A (en) | 1994-08-22 | 1999-09-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzene compound and pharmaceutical use thereof |
US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
US6043224A (en) * | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
JPH11246434A (ja) * | 1998-02-25 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | baxの低下及び/又はbcl−2の増加誘導剤 |
JP2002505868A (ja) | 1998-03-09 | 2002-02-26 | スミスクライン・ビーチャム・コーポレイション | ヒトEDG−1cポリヌクレオチドおよびポリペプチドおよびその使用法 |
JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
CZ20031910A3 (cs) * | 2000-12-11 | 2003-12-17 | Tularik Inc. | Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek |
US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
EP1426762A4 (en) * | 2001-08-08 | 2007-05-09 | Chugai Pharmaceutical Co Ltd | DRUGS FOR CARDIAC DISEASES |
US20040058894A1 (en) * | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
-
2004
- 2004-06-18 CN CNB2004800175481A patent/CN100431534C/zh not_active Expired - Fee Related
- 2004-06-18 AU AU2004253473A patent/AU2004253473B2/en not_active Ceased
- 2004-06-18 PT PT04776717T patent/PT1643983E/pt unknown
- 2004-06-18 CN CN200810212366A patent/CN101518524A/zh active Pending
- 2004-06-18 CA CA2778126A patent/CA2778126A1/en not_active Abandoned
- 2004-06-18 PL PL04776717T patent/PL1643983T3/pl unknown
- 2004-06-18 MX MXPA05014216A patent/MXPA05014216A/es active IP Right Grant
- 2004-06-18 CA CA2778309A patent/CA2778309C/en not_active Expired - Fee Related
- 2004-06-18 WO PCT/US2004/019420 patent/WO2005002559A2/en active Application Filing
- 2004-06-18 EP EP04776717A patent/EP1643983B1/en not_active Expired - Lifetime
- 2004-06-18 CA CA2529318A patent/CA2529318C/en not_active Expired - Fee Related
- 2004-06-18 DE DE602004027045T patent/DE602004027045D1/de not_active Expired - Lifetime
- 2004-06-18 US US10/562,305 patent/US7838562B2/en not_active Expired - Fee Related
- 2004-06-18 JP JP2006517361A patent/JP2007523858A/ja not_active Withdrawn
- 2004-06-18 ES ES04776717T patent/ES2342396T3/es not_active Expired - Lifetime
- 2004-06-18 BR BRPI0411831-6A patent/BRPI0411831A/pt not_active IP Right Cessation
- 2004-06-18 AT AT04776717T patent/ATE466572T1/de active
-
2010
- 2010-09-30 US US12/894,783 patent/US9101575B2/en not_active Expired - Fee Related
-
2014
- 2014-01-07 JP JP2014001034A patent/JP2014088421A/ja active Pending
-
2015
- 2015-06-18 US US14/743,352 patent/US20150283154A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101518524A (zh) | 2009-09-02 |
US20080039530A1 (en) | 2008-02-14 |
US20110015159A1 (en) | 2011-01-20 |
ATE466572T1 (de) | 2010-05-15 |
US20150283154A1 (en) | 2015-10-08 |
CA2529318A1 (en) | 2005-01-13 |
WO2005002559A3 (en) | 2005-04-14 |
CA2778126A1 (en) | 2005-01-13 |
EP1643983A2 (en) | 2006-04-12 |
CN100431534C (zh) | 2008-11-12 |
AU2004253473B2 (en) | 2010-03-04 |
CA2778309A1 (en) | 2005-01-13 |
DE602004027045D1 (de) | 2010-06-17 |
CA2529318C (en) | 2013-09-17 |
CN1826104A (zh) | 2006-08-30 |
PL1643983T3 (pl) | 2010-10-29 |
US9101575B2 (en) | 2015-08-11 |
MXPA05014216A (es) | 2006-03-13 |
US7838562B2 (en) | 2010-11-23 |
AU2004253473A1 (en) | 2005-01-13 |
PT1643983E (pt) | 2010-06-18 |
CA2778309C (en) | 2014-12-02 |
JP2007523858A (ja) | 2007-08-23 |
WO2005002559A2 (en) | 2005-01-13 |
ES2342396T3 (es) | 2010-07-06 |
JP2014088421A (ja) | 2014-05-15 |
EP1643983B1 (en) | 2010-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411831A (pt) | métodos de inibição da permeabilidade vascular e apoptose | |
AR123240A2 (es) | SAL DICLORHÍDRICA O DIBENCENSULFÓNICA DE 2-FLUORO-N-METIL-4-[7-(QUINOLIN-6-ILMETIL)IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-IL]BENZAMIDA, O HIDRATOS O SOLVATOS DE LAS MISMAS; COMPOSICIÓN; MÉTODOS PARA INHIBIR LA ACTIVIDAD DE UNA TIROSINA QUINASA RECEPTORA, LA VÍA DE SEÑALIZACIÓN DE QUINASA HGF / c-MET EN CÉLULAS, LA ACTIVIDAD PROLIFERATIVA DE CÉLULAS, EL CRECIMIENTO TUMORAL EN PACIENTES, LA METÁSTASIS TUMORAL EN UN PACIENTE; MÉTODO PARA TRATAR UNA ENFERMEDAD ASOCIADA CON LA DESREGULACIÓN DE LA VÍA DE SEÑALIZACIÓN DE HGF / c-MET EN PACIENTES, CÁNCER EN PACIENTES; PROCESO PARA PREPARAR DICHOS HIDRATOS Y DICHAS SALES; Y COMPUESTOS RELACIONADOS | |
EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
UA98629C2 (ru) | Соединения и способ модуляции киназ | |
UA111933C2 (uk) | Піролопіридини як інгібітори кінази | |
EA201000130A1 (ru) | Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы | |
ATE554725T1 (de) | Chirurgische artikel zur behandlung von beckenerkrankungen | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
EA200901486A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
MX2012003539A (es) | Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac). | |
GT200800143A (es) | Derivados de pirimidina utilizados como inhibidores de cinasa pi-3 | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
DK2712610T3 (da) | Fremgangsmåder til fremstilling af cykliske, lipidimplantater til intraokulær anvendelse | |
TW200634006A (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
WO2008028141A3 (en) | Raf inhibitor compounds and methods of use thereof | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
PA8680201A1 (es) | Proceso de elaboración para tigeciclina | |
EA201100255A1 (ru) | 5-алкинилпиримидины | |
EA200802111A1 (ru) | Имплантаты для лечения состояний, ассоциируемых с допамином | |
EA200702253A1 (ru) | Фармацевтическая композиция | |
RS20090002A (en) | Ep2 agonists | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
MX2007010752A (es) | Usos oftalmicos de moduladores de receptor s1p. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |